Last reviewed · How we verify

Phase Ia dose-escalation part of FB849 Monotherapy

1ST Biotherapeutics, Inc. · Phase 1 active Small molecule Quality 0/100

Phase Ia dose-escalation part of FB849 Monotherapy is a Small molecule drug developed by 1ST Biotherapeutics, Inc.. It is currently in Phase 1 development. Also known as: FB849.

At a glance

Generic namePhase Ia dose-escalation part of FB849 Monotherapy
Also known asFB849
Sponsor1ST Biotherapeutics, Inc.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Phase Ia dose-escalation part of FB849 Monotherapy

What is Phase Ia dose-escalation part of FB849 Monotherapy?

Phase Ia dose-escalation part of FB849 Monotherapy is a Small molecule drug developed by 1ST Biotherapeutics, Inc..

Who makes Phase Ia dose-escalation part of FB849 Monotherapy?

Phase Ia dose-escalation part of FB849 Monotherapy is developed by 1ST Biotherapeutics, Inc. (see full 1ST Biotherapeutics, Inc. pipeline at /company/1st-biotherapeutics-inc).

Is Phase Ia dose-escalation part of FB849 Monotherapy also known as anything else?

Phase Ia dose-escalation part of FB849 Monotherapy is also known as FB849.

What development phase is Phase Ia dose-escalation part of FB849 Monotherapy in?

Phase Ia dose-escalation part of FB849 Monotherapy is in Phase 1.

Related